Noopept
Dipeptide nootropic; technically a peptide derivative.
What it is
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, also called GVS-111) is a synthetic dipeptide nootropic developed in Russia in the 1990s. It is technically a peptide derivative rather than a true peptide — the structure includes an ethyl ester modification that distinguishes it from natural amino acid sequences.
Noopept is approved as a pharmaceutical in Russia for cognitive disorders and is widely used in Russian clinical practice. It has not received FDA approval in the US. Available through licensed compounding pharmacies.
Mechanism of action
Noopept’s proposed mechanisms include:
- BDNF and NGF upregulation in hippocampal regions
- Cholinergic effects supporting memory and learning
- Anti-anxiety effects through GABAergic mechanisms
- Neuroprotective effects in animal models of cognitive impairment
Despite the dipeptide structure, Noopept has small-molecule-like pharmacokinetics with oral bioavailability, distinguishing it from most peptide-based interventions.
Clinical evidence
Russian clinical research has demonstrated efficacy in cognitive impairment, particularly cerebrovascular cognitive disorders and post-traumatic cognitive syndromes. Western RCT replication is limited. The pharmaceutical approval in Russia provides regulatory validation that has not been replicated elsewhere.
Why we don’t prescribe it at The Tide
Several factors limit our use of Noopept:
- Not strictly a peptide: Noopept falls outside our peptide-focused practice scope, with structure and pharmacology more aligned with small-molecule nootropics
- Cognitive support strategies: we have peptide options (Semax, Cerebrolysin) with substantial clinical evidence for our patients’ typical concerns
- Cognitive symptoms warrant evaluation: we encourage appropriate medical workup of cognitive concerns before empiric trials of any cognitive enhancer
Side effects and contraindications
Generally well-tolerated in published Russian use. Possible side effects: mild headache, sleep disturbance, mood changes. Avoided in pregnancy, breastfeeding, severe psychiatric conditions requiring appropriate care.